At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 405 enrolled
Drug / intervention
Peramivir +1 moredrug
Likely dose
Peramivir 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
In Brief
A Phase 2 clinical trial evaluating Peramivir and Placebo for Acute, Uncomplicated Human Influenza. Completed, enrolled 405 participants across 123 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute, Uncomplicated Human Influenza
CountriesAustralia, New Zealand, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionApr 2009
Study CompletionOct 2009
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.0 years ago
Interventions
Peramivirdrug
600 mg peramivir administered as bilateral 2-mL intramuscular injection
Placebodrug
Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.